POLQ: A drug target and biomarker for various diseases (G10721)

Target Name: POLQ

NCBI ID: G10721

POLQ: A drug target and biomarker for various diseases

POLQ, or poly (1,3-diamino-2,4,5-trihydroxybenzene), is a drug target and a biomarker that has been identified in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. POLQ is a small molecule that is derived from the amino acid Asp221. It has been shown to play a crucial role in the development and progression of these diseases, and as a potential drug target, it has been the focus of extensive research in the pharmaceutical industry.

POLQ Structure and Function

POLQ is a short, linear molecule that consists of 22 amino acid residues. It has a characteristic pyridine side chain and a hydrophobic interior. The pyridine side chain is responsible for the molecule's pKa, which is an important parameter that determines its binding to protein targets. The hydrophobic interior is responsible for the molecule's stability and its ability to interact with other molecules.

POLQ has been shown to play a role in various cellular processes, including cell signaling, apoptosis, and inflammation. It has been shown to interact with several protein targets, including Bcl-2, p53, and NF-kappa-B. These interactions have led to the conclusion that POLQ may be a drug target for various diseases.

POLQ as a Drug Target

POLQ has been shown to be a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, POLQ has been shown to promote the growth and survival of cancer cells. It has been shown to interact with the anti- apoptosis protein Bcl-2, which is a known drug target for cancer. By inhibiting Bcl-2, POLQ has been shown to induce apoptosis in cancer cells.

In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, POLQ has been shown to contribute to the development and progression of these diseases. It has been shown to interact with the neurotransmitter dopamine, which is involved in the regulation of mood, appetite, and movement.

In autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, POLQ has been shown to play a role in the development and progression of these diseases. It has been shown to interact with the immune system protein, PDGF-1.

POLQ as a Biomarker

POLQ has also been shown to be a potential biomarker for various diseases.

In cancer, POLQ has been shown to be a biomarker for the disease. It has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to be associated with cancer progression and poor prognosis.

In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, POLQ has been shown to be a biomarker for the disease. It has been shown to be expressed in the brains of individuals with these diseases, and it has been shown to be associated with the progression of these diseases.

In autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, POLQ has been shown to be a biomarker for the disease. It has been shown to be expressed in the blood and tissues of individuals with these disorders, and it has been shown to be associated with the progression of these diseases.

Conclusion

POLQ is a small molecule that has been shown to play a crucial role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function, as well as its potential as a drug target and biomarker, make it an attractive target for

Protein Name: DNA Polymerase Theta

Functions: DNA polymerase that promotes microhomology-mediated end-joining (MMEJ), an alternative non-homologous end-joining (NHEJ) machinery triggered in response to double-strand breaks in DNA (PubMed:25642963, PubMed:25643323). MMEJ is an error-prone repair pathway that produces deletions of sequences from the strand being repaired and promotes genomic rearrangements, such as telomere fusions, some of them leading to cellular transformation (PubMed:25642963, PubMed:25643323). POLQ acts as an inhibitor of homology-recombination repair (HR) pathway by limiting RAD51 accumulation at resected ends (PubMed:25642963). POLQ-mediated MMEJ may be required to promote the survival of cells with a compromised HR repair pathway, thereby preventing genomic havoc by resolving unrepaired lesions (By similarity). The polymerase acts by binding directly the 2 ends of resected double-strand breaks, allowing microhomologous sequences in the overhangs to form base pairs. It then extends each strand from the base-paired region using the opposing overhang as a template. Requires partially resected DNA containing 2 to 6 base pairs of microhomology to perform MMEJ (PubMed:25643323). The polymerase activity is highly promiscuous: unlike most polymerases, promotes extension of ssDNA and partial ssDNA (pssDNA) substrates (PubMed:18503084, PubMed:21050863, PubMed:22135286). Also exhibits low-fidelity DNA synthesis, translesion synthesis and lyase activity, and it is implicated in interstrand-cross-link repair, base excision repair and DNA end-joining (PubMed:14576298, PubMed:18503084, PubMed:19188258, PubMed:24648516). Involved in somatic hypermutation of immunoglobulin genes, a process that requires the activity of DNA polymerases to ultimately introduce mutations at both A/T and C/G base pairs (By similarity)

More Common Targets